Avalon Ventures


First drug discovery startup emerges from GSK-Avalon deal to take on celiac disease

The $495 million innovation collaboration between GlaxoSmithKline and early-stage investor Avalon Ventures has produced its first fruits in the form of a company initially focused on treating celiac disease. Sitari Pharmaceuticals launched today with a $10 million Series A from Avalon and GSK and technology from Stanford University. It’s still in the early discovery phase, […]